Trillium Asset Management LLC Lowers Stock Holdings in Icon Plc $ICLR

Trillium Asset Management LLC cut its stake in shares of Icon Plc (NASDAQ:ICLR) by 5.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 35,773 shares of the medical research company’s stock after selling 2,049 shares during the period. Trillium Asset Management LLC’s holdings in Icon were worth $5,204,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in ICLR. Equity Investment Corp purchased a new stake in shares of Icon during the 2nd quarter valued at $82,264,000. Cantillon Capital Management LLC purchased a new stake in shares of Icon during the 2nd quarter valued at $67,663,000. First Pacific Advisors LP grew its stake in shares of Icon by 76.3% during the 2nd quarter. First Pacific Advisors LP now owns 964,120 shares of the medical research company’s stock valued at $140,231,000 after buying an additional 417,173 shares during the period. Coho Partners Ltd. purchased a new stake in shares of Icon during the 2nd quarter valued at $33,649,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Icon by 18.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,060,499 shares of the medical research company’s stock valued at $157,887,000 after buying an additional 162,853 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Stock Up 0.5%

Shares of Icon stock opened at $163.70 on Thursday. Icon Plc has a twelve month low of $125.10 and a twelve month high of $231.89. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a market cap of $13.22 billion, a price-to-earnings ratio of 22.15, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23. The company has a fifty day moving average price of $177.72 and a 200 day moving average price of $159.99.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $3.31 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.03. Icon had a net margin of 7.40% and a return on equity of 10.58%. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the previous year, the business posted $3.35 EPS. The firm’s revenue was up .6% compared to the same quarter last year. Equities research analysts forecast that Icon Plc will post 13.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on ICLR shares. TD Cowen lowered their price objective on shares of Icon from $183.00 to $172.00 and set a “hold” rating for the company in a research note on Friday, October 24th. UBS Group set a $220.00 price target on shares of Icon in a research report on Friday, October 24th. Evercore ISI upped their price target on shares of Icon from $170.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Barclays decreased their price target on shares of Icon from $190.00 to $185.00 and set an “equal weight” rating for the company in a research report on Friday, October 24th. Finally, Truist Financial upped their price target on shares of Icon from $187.00 to $234.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $207.14.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.